Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients with Severe Insomnia
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Pharmanovia
- Target Recruit Count
- 100
- Registration Number
- NCT06053840
- Locations
- 🇬🇧
Lindus Health, The Leather Market Weston Street, Bermondsey,, London, United Kingdom
News
Catumaxomab Receives European Marketing Authorization for Malignant Ascites Treatment
Catumaxomab, a first-in-class trifunctional antibody, has been granted European Commission marketing authorization for malignant ascites.
Lindis Biotech and Pharmanovia Partner to Relaunch Catumaxomab for Malignant Ascites
Lindis Biotech has partnered with Pharmanovia to relaunch Catumaxomab, a bifunctional antibody therapy, following a positive review from the EMA's Committee for Medicinal Products for Human Use.
Pharmanovia In-Licenses Catumaxomab for Malignant Ascites Treatment
Pharmanovia has secured exclusive rights to commercialize catumaxomab, a trifunctional bispecific monoclonal antibody, for treating malignant ascites.